UBS Defends Informatica (INFA); Q2 A Bump After 31 Straight Quarters of Meet or Beat - Buy The Dip!
Tweet Send to a FriendGet Alerts INFA Hot Sheet
Price: $36.17 -0.22%
Rating Summary:
11 Buy, 10 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 21
Rating Summary:
11 Buy, 10 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 21
Trade INFA Now!
UBS maintains a 'Buy' on Informatica (NASDAQ: INFA) price target of $45.00 (from $55.00).
Analyst, Brent Thill, said, "Q2's miss was very uncharacteristic for a company with a sterling track record of meeting or exceeding expectations for the last 31 Quarters. However, with shares at 3.4x our newly revised CY13 sales estimates, we find the stock very compelling."
FY12 EPS estimate lowered from $1.63 to $1.45 and FY13 from $1.85 to $1.60. FY12 revenues cut from $903M to $825M and FY13 from $1.0B to $9.07M.
For an analyst ratings summary and ratings history on Informatica click here. For more ratings news on Informatica click here.
Shares of Informatica closed at $43.37 yesterday, with a 52 week range of $34.15-$62.42.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Brent Thill, said, "Q2's miss was very uncharacteristic for a company with a sterling track record of meeting or exceeding expectations for the last 31 Quarters. However, with shares at 3.4x our newly revised CY13 sales estimates, we find the stock very compelling."
FY12 EPS estimate lowered from $1.63 to $1.45 and FY13 from $1.85 to $1.60. FY12 revenues cut from $903M to $825M and FY13 from $1.0B to $9.07M.
For an analyst ratings summary and ratings history on Informatica click here. For more ratings news on Informatica click here.
Shares of Informatica closed at $43.37 yesterday, with a 52 week range of $34.15-$62.42.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- AcelRx (ACRX) Target Lifted at Jefferies
- UPDATE: UBS Starts Insmed (INSM) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
UBS
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
